Durata seeks FDA OK for dalbavancin in ABSSSI
This article was originally published in Scrip
Executive Summary
Shares of Durata Therapeutics rose as much as 3.6% on 27 September on the news the company is seeking the FDA's approval to market dalbavancin as a treatment for patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive microorganisms, including methicillin resistant Staphylococcus aureus (MRSA).